Drugs / UTAA17
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06279026 | Apr 2024 → Apr 2027 expected | refractory plasma cell neoplasm | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UTAA17 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06279026 ↗ |
| Modality | Cell therapy | “CAR+γδT cell transfusions” NCT06279026 ↗ |